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Background: Therapeutic adherence of patients with chronic obstructive pulmonary disease (COPD) is poor. This
study evaluated the effectiveness of a multifactorial intervention on improving the therapeutic adherence in
chronic obstructive pulmonary disease (COPD) patients with scheduled inhalation therapy.
Methods: The study design consisted of a randomised controlled trial in a primary care setting. 146 patients
diagnosed with COPD were randomly allocated into two groups using the block randomisation technique. One-year
follow-ups with three visits were performed. The intervention consisted of motivational aspects related to adherence
(beliefs and behaviour) in the form of group and individual interviews, cognitive aspects in the form of information
about the illness and skills in the form of training in inhalation techniques. Cognitive-emotional aspects and training
in inhalation techniques were reinforced during all visits of the intervention group. The main outcome measure was
adherence to the medication regimen. Therapeutic adherence was determined by the percentage of patients classified
as good adherent as evaluated by dose or pill count.
Results: Of the 146 participants (mean age 69.8 years, 91.8% males), 41.1% reported adherence (41.9% of the control
group and 40.3% of the intervention group). When multifactorial intervention was applied, the reported adherence was
32.4% for the control group and 48.6% for the intervention group, which showed a statistically significant difference
(p = 0.046). Number needed to treat is 6.37. In the intervention group, cognitive aspects increased by 23.7% and
skilled performance of inhalation techniques increased by 66.4%. The factors related to adherence when multifactorial
intervention was applied were the number of exacerbations (OR = 0.66), visits to health centre (OR = 0.93) and devices
(OR = 2.4); illness severity (OR = 0.67), beta-2-adrenergic (OR = 0.16) and xantine (OR = 0.19) treatment; activity
(OR = 1.03) and impact (OR = 1.03) scales of the Saint George Respiratory Questionnaire.
Conclusion: Application of the multifactorial intervention designed for this study (COPD information, dose
reminders, audio-visual material, motivational aspects and training in inhalation techniques) resulted in an
improvement in therapeutic adherence in COPD patients with scheduled inhalation therapy.
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Chronic obstructive pulmonary disease (COPD) is char-
acterised by airflow limitations that are not fully revers-
ible. COPD is expected to become one of the major
health challenges of the next few decades [1]. Prevalence
surveys suggest that nearly one-quarter of adults aged
40 years and older have mild airflow obstruction [2-4].
COPD is presently the fourth leading cause of death, but
the World Health Organization (WHO) predicts that it
will become the third leading cause of death by 2030 [5],
as mortality resulting from cardiac diseases and stroke
decreased over the last 30 years, while that of COPD
doubled over the same period [6].
As with all chronic diseases, therapy non-adherence in
patients with COPD is a common problem and contrib-
utes to adverse health outcomes, reduced quality of life
and increased healthcare expenditures [7]. According to
the WHO, patient adherence to long-term therapy aver-
ages 50% [8]. Adherence rates in clinical trials may be as
high as 70 to 90% [9-11], but in clinical practice, they
range from 10 to 40% [12-14].
Several factors are related to adherence in COPD
patients. Medication regimens are particularly vulnerable
to adherence problems because of the chronic nature of
the disease, the use of multiple medications (polyphar-
macy) and periods of clinical remission [15,16]. Selection
of the medication and the delivery device usually depend
on the efficacy of the different inhaled medications and
devices, but these choices may be influenced by factors
that are not clinically relevant, such as the ability of the
patient to use the device, which also affects treatment
adherence [15]. Moreover, patients often need to make
important behavioural and lifestyle changes, which are
also very important to treatment adherence [15].
Few studies exist on interventions to improve thera-
peutic adherence in COPD patients and other important
aspects of disease management. Most of these existing
studies have also involved asthmatic patients [17-22]. The
studies have focused mainly on quantifying adherence and
less on exploring the factors that affect non-adherence,
although most of the authors highlight the need to work
in motivational and cognitive ways to improve patient
understanding of both their illness and treatment [22].
Specific studies that consider educational programs ex-
clusively designed for COPD patients show significant im-
provement in patient management of the disease, including
fewer exacerbations, decreases in the use of rescue medica-
tion and improved knowledge about inhaler use [19,21].
These programs include information about the illness,
treatment, the importance of adherence, managing exacer-
bations, instructions on inhalation techniques and recom-
mendations regarding the proper time to ask for a doctor’s
advice. In some cases, counselling to cease smoking or
referrals to independent programs are also included.The main objective of this study was to evaluate the
effectiveness of a multifactorial intervention (COPD
information, dose reminders, audio-visual material, mo-
tivational aspects and training in inhalation techniques)
on improving the therapeutic adherence in COPD pa-
tients with scheduled inhalation therapy after 1 year of
follow-up with two reinforcement visits (3 and 6 months
after intervention). The second objective was to de-
scribe the change in the functional status and health
related quality of life and the possible modifying factors
related to adherence when multifactorial intervention is
applied.Methods
The study was approved by the by the Ethical Commit-
tees of the Primary Care Trust Málaga (01/03/07) and
Axarquía (13/05/08) and by the Committee of Clinical
Trials of the University Hospital Virgen de la Victoria,
Málaga (30/11/07). The study protocol was reviewed by
the Spanish Agency of Medicine and Health Products.Participants, design and setting
The study protocol has been published elsewhere [23].
In brief, we used a multicentre randomised controlled
trial enrolled a sample consisting of 146 patients with
COPD selected by a non-probabilistic consecutive sam-
pling method. The inclusion criteria were as follows: con-
firmed COPD diagnosis registered in the patient’s clinical
record, clinical assistance at primary care centres in the
Malaga area, prescription of scheduled inhalation therapy
and written informed consent. Patients were excluded if
they had other respiratory conditions that are not included
in the COPD definition (bronchiectasis, asthma or cystic
fibrosis) or cognitive impairment problems registered in
their clinical record (dementia, Alzheimer’s, Parkinson’s or
cognitive decline).
The sample size was calculated to detect an adherence
percentage difference between groups of 25%, with a
statistical power of 80% and a confidence level of 95%,
assuming a percentage of expected losses of 20%.
Patients were contacted by telephone using their
health centre records and invited to participate; they
then received an appointment at the health centre. At
this first appointment (inclusion visit), patients were
given more detailed information about the study, and if
they agreed to participate, they signed the written con-
sent form.
Subjects were divided randomly into two groups, a con-
trol group and an intervention group, using the block
randomisation technique (blocks of four patients). All of
the patients attended the same number of appointments.
The follow-up for both groups consisted of three visits at
3, 6 and 12 months.
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The intervention consisted of two activities, a group
session at the beginning of the study and individual inter-
ventions during the follow-up visits. In both activities we
applied a multifactorial educational strategy with three
parts considered to be the most relevant aspects related to
treatment adherence in patients with COPD [21]:
– Part 1: Motivational aspects used to improve
adherence. Focus groups were used to reveal patient
experiences and points of view about their illness
and treatment, including treatment adherence [24].
This session was videotaped with the patients’
formal consent for later analysis. Researchers
analysed these videos to determine the main
motivational aspects to focus on during the
individual visits [25].
– Part 2: Cognitive aspects related to treatment
adherence. The intervention group received
information about the disease so they could be more
confident and more conscious about the importance
of their daily treatment.
– Part 3: Skills development involving training in
inhalation techniques. The intervention group was
trained in the use of their inhalers according to
SEPAR (Sociedad Española de Neumología y Cirugía
Torácica) guidelines [26], received explanations as to
why a good technique is important, and practiced
the proper technique with placebo inhalers.
Groups consisted of 6 to 9 patients. The group session
lasted approximately 2 hours, including the patient’s
reception, the distribution of materials, the description
of the contents and the farewell. All group sessions were
conducted by two professionals with special training in
motivational techniques and in the use of inhaler de-
vices. Audio-visual and written materials were used in
parts 2 and 3 of the intervention (a leaflet describing the
most relevant aspects of the disease and a scheme on
inhalation techniques). The individual visits were con-
ducted by the same professional for each patient.
The information used to plan the individual interven-
tion employed during the follow-up visits was extracted
from the group session by at least two researchers using
qualitative methods [24].
Outcomes definition and measurement
The primary outcome was adherence to (or compliance
with) a medication regimen, which is generally defined
as “the extent to which a person’s behaviour—taking
medication, following a diet and/or executing lifestyle
changes—corresponds with agreed recommendations
from a health care provider” [27]. Therapeutic adher-
ence represented the percentage of patients classifiedas good adherent as evaluated using dose or pill count.
The measurement of doses or pill was made counting the
number of doses register in the counter of device or con-
sidering the number of pills lacking in the blister packs
of the prescribed medication.
The dose/pill count is the number of pills or doses
taken divided by the number of pills or doses prescribed
and then multiplied by 100 (expressed as a percentage)
[28]. According to the recommendations in Sackett et al.
[29], it is considered good adherence when the counting
result is between 80% (20% of doses/pills missed) and
110% (the patient inhales 10% more doses/pills) of the
dose/pill count prescribed.
The cognitive aspects were measured using the
Batalla Test [30]; this test provides information about
the patients’ knowledge of their illness. The test has
three questions, adapted to COPD, and we was consid-
ered a good knowledge when the answers properly the
complete questionnaire.
Patient’s skills at performing inhalations techniques
were measured following SEPAR guidelines [26], using a
schedule containing the main steps of correct technique.
The secondary outcomes that were measured included
functional status by forced spirometry (following SEPAR
guidelines [31]) and health-related quality of life as de-
termined by the St. George respiratory questionnaire
(SGRQ) [32] and the EuroQoL-5D questionnaire [33].
Covariates
Factors considered to be associated with adherence
were included as independent variables. General factors
consist of age, educational level (low: no schooling or
can only read and write) and co-morbidities. Disease-
specific factors consist of time since diagnosis, smoking
habits (smokers, non-smokers, numbers of cigarettes,
years smoking), prescribed COPD treatment, number of
devices, exacerbations and health care visits because of
COPD (defined using patient health centre records).
Statistical analysis
A descriptive statistical analysis was performed for all of
the study variables. We calculated the mean, median and
standard deviations for quantitative variables and the
absolute and relative frequencies for qualitative variables.
We conducted several univariate analyses: between-
group comparison at baseline, comparison between the
initial sample and the final sample (impact of losses on
sample structure) and exploration of the relationship
between the primary outcome (adherence) and all of the
independent variables at the end of the study. The chi-
squared test or analysis of variance (ANOVA) was used.
The relative risk reduction (RRR), the absolute risk
reduction (ARR) and the number needed to treat (NNT)
were calculated.
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random-effects estimations were used for the primary
outcome [treatment adherence (yes/no)]. The inter-
vention was considered the predictive variable, and the
rest of the independent measures that were statistically
significant during univariate analysis or that were con-
sidered clinically relevant because they were related to
adherence in other studies [15,16,34-36] were consid-
ered the possible modifying factors.
To account for losses at the end of study, we built four
partial models considering different independent variables
and, at the end, we performed a final model to describe
the modifying factors in our study. Model 1 was built
using the sociodemographic profile (cohort, age and
educational level). Model 2 included the utilisation of
resources (cohort, number of general visits to the health
care centre or because of COPD). Model 3 was built
considering functional characteristics (cohort, spirom-
etry pattern, severity level, FEV1 and FVC percentages,
number of exacerbations and SGRQ scales). Model 4
included treatment (cohort, Beta-2 adrenergic agonist,
inhaled and oral corticosteroids, s, xanthine treatment
and the number of devices). The final model was built
using cohort, age, educational level, HBP, the number of
general visits to the health care centre, severity level,
the number of exacerbations, the impact and activity
scales of the SGRQ, Beta-2 adrenergic agonist, s, xanthine
treatment and the number of devices.
The analysis was performed under an intention-to-treat
procedure. We used a 5% significance level (f = 0.05) and
the SPSS statistical package, version 15.0, to run the pro-
posed analysis. Logit modelling was built using the Stata
statistical package, version 11.1.
Results
Recruitment and follow-up
A total of 1553 people were screened for inclusion visit
in the study. Three hundred and ninety seven did not
fulfil any of the inclusion criteria or had at least one of
the exclusion criteria and were excluded from the study.
Figure 1 shows the flow of patients in the study and rea-
sons for exclusion.
Patients’ baseline characteristics
The sample consisted of 146 patients with COPD. The
patients were predominantly male (91.8%), with a mean
age of 69.08 years (95% CI, 67.58-70.44 years), and 78.1%
had a low educational level (4.1% had no studies, 29.5%
were able to read and write, and 44.5% had a primary edu-
cation) (Table 1).
The mean body mass index was 30.78 kg/m2 (95% CI,
28.78-32.78). In terms of smoking, 93.8% of the patients
had smoked, and 32.2% were active smokers, with a
mean of 62.84 pack-years (95% CI, 55.34-70.34). Mostpatients suffered from at least one additional patho-
logical condition, the most prevalent of which was high
blood pressure (49.3%), followed by diabetes (32.2%) and
osteoarthritis (31.5%). The patients had experienced at
least one exacerbation over the last year, with a mean
value of 0.87 exacerbations (95% CI, 0.68-1.06). Patients
had consulted with the health centre because of COPD a
mean of 1.8 times over the last year (95% CI, 1.47-2.13),
which accounted for 26% of the total health visits.
The study included patients who had a COPD diagno-
sis in their clinical records, 91% of which were based on
spirometric and clinical criteria. The mean time of
COPD diagnosis was 4.43 years (95% CI, 3.56-5.3). The
spirometry performed in the study revealed a mean
FEV1 of 67.58% (95% CI, 64.58-71.08), with a predom-
inant obstructive pattern (51.4%). Based on SEPAR [37]
values, severity was distributed as follows: 37.7% mild
stage, 43.5% moderate stage and 18.8% severe stage.
The major drugs prescribed for COPD were as follows:
80.1% of the patients were taking Beta-2 adrenergic ago-
nists, 77.4% were taking anti-cholinergic drugs, and
70.5% had been prescribed inhaled corticosteroids. We
also observed that 8.2% had a xanthine prescription,
11.6% were being treated with mucolytics, and 0.7% were
being treated with oral corticosteroids. In most cases,
patients were receiving combined therapy with more
than one drug. The most frequent treatment (39.7%)
was a 3-drug combination, normally consisting of an
anti-cholinergic with a Beta-2 adrenergic agonist and an
inhaled corticosteroid.
The health-related quality of life measured by the
SGRQ in the total sample showed the following results
according to its different scales: symptoms 41.2 (95%
CI, 38.01-44.39), activity 51.86 (95% CI, 48.43-55.29),
impact 28.1 (95% CI, 25.16-31.04) and total 37.47 (95%
CI, 34.61-40.33).
According to the EuroQoL-5D-3 L scores in the total
sample, less impairment was seen in mobility (56.8%);
performance of main, family or leisure activities (78.8%);
and self-care (84.2%). Additionally, 67.8% showed no
anxiousness or depression, and 45.2% had no pain or
discomfort.
In Table 1, we show the baseline comparison between
the intervention and control groups; no significant dif-
ferences were observed between groups except for high
blood pressure (the intervention group had more hyper-
tensive patients) (p = 0.032).
At the end of the follow-up period, the dropout rate
was 28.8% (42 patients: 27 were excluded because they
gave the inclusion criteria out, 16 of them did not attend
the group session in intervention group; 6 did not attend
the appointment; 4 refuse to follow in the study; 3 were
unreachable and 2 deceased). We found differences in
the spirometric pattern, there were less patients with
Figure 1 Study scheme.
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end of study: 33%; p = 0.017). The percentage of FEV1
(baseline: 67.83%; end of study: 60.38%; p = 0.006), FVC
(baseline: 82.75%; end of study: 69.71%; p = 0.001), the
number of exacerbations (baseline: 0.87; end of study:
0.43; p = 0.001), the number of general visits to the
health centre (baseline: 6.93; end of study: 3.53; p = 0.001)
or visits because of COPD (baseline: 1.8; end of study: 1;
p = 0.001) were lower at the end of study and the oralcorticosteroid prescription (baseline: 0.0068%; end of
study: 0.046%; p = 0.039) was higher. No differences
were found between patients lost to follow up in the
intervention or in the control group.
Intervention effectiveness
The change in adherence level according to dose/pill
count in the total sample and in each group using per
protocol analysis shows that the intervention group
Table 1 Baseline comparison between the study groups
Variables (measure) CG IG p
Adherence (%) 41.9 40.3 0.843*
Sex (% males) 91.9% 91.7% 0.96*
Age (years) 68.59 (66.4-70.78) 69.57 (67.74-71.4) 0.509**
Low Educational Level 81% 75% 0.683*
Current Smoking (%) 33.8% 30.6% 0.676*
Smoking history
(Pack-years)
58.67 (48.68-68.66) 67.07 (55.88-78.26) 0.275**
Cigarettes/day 21.32 (19.3-23.34) 19.45 (15.87-23.03) 0.683**
BMI (Kg/m2) 31.42 (27.47-35.37) 30.11 (29.06-31.16) 0.538**
Comorbidity
• HBP (%) 40 58,3 0.032*
• DM (%) 25.7 38.9 0.088*
• OA (%) 33.8 29.2 0.548*
Diagnosis time (years) 4.27 (3.57-4.97) 4.61 (3.63-5.59) 0.585**
Pattern (%) 0.673*
• Obstructive 47.8 54.9
• Restrictive 13 12.7
• Mixed 39.1 32.4
Severity (%) 0.630*
• Mild 34.8 40.6
• Moderate 43,5 43,5
• Severe 21.7 15.9
Exacerbations per years 0.82 (0.59-1.05) 0.92 (0.67-1.17) 0.642**
Visits HC due COPD 1.56 (1.15-1.97) 2.04 (1.54-2.54) 0.162**
Treatment (%)
• Anticholinergic 77 77.8 0.914*
• Beta-2 adrenergic 79.7 80.6 0.900*
• Inhaled corticosteroids 74.3 66.7 0.310*
• Xanthine 6.8 9.7 0.514*
Number of Devices (%) 0.913*
• 1 29.7% 30.6%
• 2/more 70.3% 69.4%
SGRQ (scores)
Total 39.53 (35,42-43.64) 35.32 (31.35-39.29) 0.152**
• Activity 52.05 (48.12-57.98) 50.62 (45.83-55.4) 0.49**
• Symptoms 42.74 (38.14-47.34) 39.62 (35.21-44.03) 0.341**
• Impact 30.66 (26.45-34.87) 25.46 (21.41-29.51) 0.085**
EuroQoL5D-3 L
(%without problem)
• Mobility 54.1 59.7 0.489*
• Self-care 82.4 86.1 0.542*
• Perform main, family
or leisure activities
77 80.6 0.601*
Table 1 Baseline comparison between the study groups
(Continued)
• Anxious or depressed 40.5 50 0.099*
• Pain or discomfort 64.9 70.8 0.207*
Quantitative variables: mean (CI 95%); Qualitative variables: %.
CG: control group; IG: intervention group; BMI: body mass index; HBP: high
blood pressure; DM: diabetes mellitus; OA: osteoarthritis HC: health center;
SGRQ: Saint George Respiratory Questionnaire.
*ji-schare test; **ANOVA test.
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the control group reached a rate of 49% (p = 0.002).
When we used intention-to-treat analysis (Figure 2), the
difference between groups remained statistically signifi-
cant (p = 0.046), and it became necessary to apply the
intervention to 6 or 7 patients to obtain another adher-
ent patient (Table 2).
Relating to cognitive aspects, the intervention group
showed an increase of 23.7% as measured by the Batalla
test [30]. At the end of study, the difference between
groups was statistically significant (p = 0.006) when the
analysis per protocol was used, but it was not statistically
significant with the intention-to-treat analysis.
Patients’ skills at performing inhalation techniques
were measured only in the intervention group, and there
was better management of the inhalation devices at the
end of the study (Figure 3).Factors related to treatment adherence
Univariate analyses
A significant difference was detected between adherence
and the intervention applied (p = 0.046). There was no
association with age, sex, educational level, smoking
habits, comorbidity or time since diagnosis. Relating to
functional status, an association was detected for spiro-
metric pattern (adherent patients had an obstructive pat-
tern 75.8% and no adherent patient had a restrictive
pattern 68.8%; p = 0.009) and FVC percentage (adherent
patients: 74.26%; no adherent patient 63.67%; p = 0.006),
but not with severity or FEV1 percentage.
An association was found between adherence and the
prescription of Beta-2 adrenergic agonists (adherent
patients: 76.2%; no adherent patient 23.8%; p = 0.031),
xanthine (adherent patients: 20%; no adherent patient
80%; p = 0,019), inhaled corticosteroids (adherent pa-
tients: 29.6%; no adherent patient 70.4%; p = 0,066) and
mucolytics (adherent patients: 18.2%; no adherent pa-
tient 81.8%; p = 0,009).
There was no association with quality of life measure-
ments and adherence. The total scale of the SGRQ was
similar in both groups, but the scores on the symptom
and activity scales were higher in non-adherent patients,





















Visit 0 (V0) Visit 1 (V1) Visit 2 (V2) Visit 3 (V3) 
Total Sample 41.1 43.2 44.5 40.4 
Control Group (CG) 41.9 44.6 51.4 32.4 
Intervention Group (IG) 40.3 41.7 37.5 48.6 
p 0.843 0.721 0.092 0.046 
Figure 2 % percentage of adherence during follow-up measured by dose/pill count. Intention to treat analysis.
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After considering the univariate analyses, we performed the
four partial fixed-effects logistic regression models described
above. All of the models were adjusted by the presence of
high blood pressure because we found a significant differ-
ence for this variable at baseline between the study groups.
The final model (Table 3) was built using a random-
effects approach considering as predictive variables those
variables that were included in the final model of the
four partial models: cohort; age; educational level; pre-
scription of Beta-2 adrenergic agonists, xanthine and
mucolitycs; the number of different devices; severity; the
number of exacerbations; the number of visits to the
health care centre; and the activity and impact scales of
the SGRQ. The final logit model obtained showed that
adherence is favoured by the multifactorial intervention
(OR = 1.88), a lower number of exacerbations (OR = 0.66),
a lower number of visits to the health centre (OR = 0.93), a
lower severity (OR = 0.677) and a lower number of devices
(OR = 2.4). In terms of quality of life, adherence is favoured
by a lower impairment of daily activities (OR = 0.978) and aTable 2 Intervention effectiveness on treatment
adherence
Parameters APP ITT
Value (95% CI) Value (95% CI)
Control 0.489 0.324
Interv 0.795 0.481
RR 1.62 (1.35-1.93) 1.48 (1.07-2.04)
RBI 0.62 0.48
ABI 0.306 (0.216-0.396) 0.157 (0.007-0.307)
NNT 3.26 (2.52-4.62) 6.37 (3.25-142.8)
RR: Relative risk; RBI: Relative benefit increase; ABI: absolute benefit increase;
NNT: number needed to treat; CI: Confidential interval. APP: analysis per
protocol; ITT: Intention to treat analysis.higher disease impact (OR = 1.03). Beta-2 adrenergic agon-
ist (OR = 0.16) and xanthine (OR = 0.199) treatments are
associated with no adherence in our model. The rho coeffi-
cient in this model was 6.07×10−6 (p = 0.498).
Discussion
The sociodemographic characteristics of our sample are
similar to those in other studies that were performed in
primary care settings [4,38-41]. COPD presents in older
ages and predominates in males. Some previous studies
have shown that the male sex is not a risk factor for
COPD, and it appears that women could be more prone
to COPD specifically because of tobacco exposure [42,43].
In our region, we retained a high prevalence in the male
sex, most likely because of the smoking habits. Tobacco is
considered one of the most important initial diagnostic
characteristics for identifying chronic obstruction, and it is
the major risk factor for COPD [44,45]. In our study,
34.2% of patients had a low educational level, which could
contribute to poorer health education and greater diffi-
culty in using health resources. Thus, we performed an
educational intervention adapted to these patients using
audio-visual material; we also determined that the ques-
tionnaires would be administered by the interviewer to
help people who did not read or write fluently.
Our prescription profile is similar to other studies [46,47]
and is concordant with national and international guide-
lines for the prescription of the major long-acting bron-
chodilator drugs [45,48]. The anti-cholinergic and Beta-2
adrenergic agonists are the most frequently prescribed
drugs. Our subjects had a high prescription level of
inhaled corticosteroids, particularly when taking into
account that they had only mild to moderate severity.
The prevalence of adherence was 41%, while the ob-
served levels of inadequate adherence were in line with










Handihaler 14 24,2 48,5 81,1
Accuhaler 35,7 45,5 63,6 92,3
Turbuhaler 14,3 44,4 28,6 80
Total 21,34 38,04 46,9 84,47
V0 V1 V2 V3
Figure 3 Percentage of patients who performs a correct inhalation technique per device after one year follow-up.
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Patients with COPD require adequate education on the
disease process, comorbidities and the use of different
medications and devices. They often need to make import-
ant behavioural and lifestyle changes as well.
Intervention efficacy
No standard intervention exists to improve adherence.
Haynes et al. [21] showed that there are many ways to
perform interventions for adherence, but few studies
exist about how to do it, possibly because of the com-
plexity of this aspect. All of the effective interventions
for long-term care were complex and included different
combinations of more convenient care, information, re-
minders, self-monitoring, reinforcement, counselling,
family therapy, psychological therapy, crisis interven-
tion, telephone follow-up and supportive care. In COPDTable 3 Treatment adherence random-effects logistic regress
Variables OR Std error
Study Group 1.887769 0.6012
Age 0.992041 0.0183
Educational level 1.653566 0.5637
Number of visit to HC 0.938932 0.0332
Severity 0.677282 0.1504
Number of exacerbation 0.66481 0.1065




Number of devices 2.4113 0.9696
SGRQ (activity scale) 0.97878 0.0120
SGRQ (impact scale) 1.0310 0.0151
Sigma_u 0.0044 0.6345
Rho 6.07e-06 0.0017
Likelihood-ratio test of rho = 0: chibar2(01) = 1.6e-05 Prob > =chibar2 = 0.498.patients, existing studies on interventions to improve
adherence are scarce, and many of them have been con-
ducted with the inclusion of asthma patients [21]. The
results are limited because the characteristics and re-
sponses to intervention are different for each disease
[21]. Recent studies on adherence in COPD patients are
centred on the description of factors that could have
influenced it [15,16]. Specific studies that consider edu-
cational programs exclusively for COPD patients show
significant improvement in patient management of the
disease, fewer exacerbations, decreases in the use of
rescue medications and improved knowledge about
inhaler use [20,21].
The intervention designed in this study shows signifi-
cant improvement in the therapeutic adherence of pa-
tients, confirming that multifactorial interventions are
appropriated for patients with COPD. Looking at theion model
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http://www.biomedcentral.com/1471-2466/14/70data of visit 2, control shows a better adherence than
intervention group, although at visit 3 the percentage of
adherent patients is greater in the intervention group.
Even though regression to mean might be a possible
explanation for the increase rate of adherent in the control
group, we think that the great amount of losses at visit 2
in this group, could explain also these results (most of the
losses may have been the less motivated and adherent
patients).
Our intervention focuses on three aspects: motivation,
knowledge and skilled inhalation technique. Motivational
aspects are related to patient beliefs and attitudes about
their illness, their treatment and their physician. We
emphasised these aspects because adherence includes a
behavioural component and behaviour is slow and diffi-
cult to change [15,36]. New strategies based on shared
decision-making appear to be the best approach to the
behavioural component because treatment adherence
includes a patient’s commitment to treatment, including
the therapeutic regimen and the behavioural changes
(smoking cessation, exercise) required to correctly manage
their COPD. Khdour et al. [36] indicate that strategies
aimed at improving COPD patient adherence must
include the establishment of a personal relationship or
partnership in which the patient feels able to discuss
their fears, concerns and personal goals. In this regard,
the motivational interview is very useful because the
patients express their doubts and fears, and the doctor
can act individually on each problem.
The second aspect of our intervention is the cognitive
improvement related to COPD found in the intervention
group, which is consistent with other studies concluding
that COPD patients classified as adherent had greater
understanding of their illness and their options for dis-
ease management [36]. Although the cognitive aspect
could be related to educational level, no association
was found in our patients. According to the literature,
independently of educational level, instruction about
the illness and its treatment is useful and has a signifi-
cant impact on adherence [15].
The last aspect of our intervention concerns training
in inhalation techniques. It is critical to evaluate whether
patients are able to use their inhaler device correctly.
Significant evidence shows that nearly 90% of patients
with COPD incorrectly use their inhalers and that many
of them display a technique that possibly delivers an
inadequate dose [15,50]. The training program included
in our intervention improved the percentage of patients
who could perform a correct inhalation technique. This
improvement was evident at the first follow-up visit
because many of the study subjects had never been
trained on inhalation techniques. Regular instruction,
supervision, and follow-up on inhalation techniques in
primary care are the responsibility of health professionals(physicians and nurses) [51]. Under real-life conditions,
inappropriate inhaler use is common and strongly cor-
relates with a lack of instruction by the caregiver
[15,52]. Because the measurement of inhalation tech-
nique was performed only in the intervention group,
we would have needed a control group to determine
the precise effect of training; however, a 66.46% in-
crease in the use of correct technique does not appear
to be entirely random. We are currently conducting a
clinical trial to test the efficacy of this training [53],
after which we will be able to quantify the effect of
intervention on inhalation techniques.
Modifying factors related to adherence when
multifactorial intervention is applied
In addition to receiving the designed multifactorial inter-
vention, the models obtained from the multivariate ana-
lysis show that adherence is also related to the number of
visits to the health centre; the number of exacerbations;
disease severity; health status as measured by the activity
and impact scales of the SGRQ; Beta-2 adrenergic agonist
and xanthine prescriptions; and the number of devices.
The more adherent patients required fewer visits to
the health centre and had fewer exacerbations, a lower
number of devices, a lower level of severity, and a lower
impact on daily activities, but with a higher disease im-
pact. Beta-2 adrenergic agonist and xanthine treatments
were associated with no adherence.
In this study, adherent patients with COPD had an
incipient diagnosis of COPD [53] (mild severity and
obstructive pattern). At this stage the illness had less of
an impact on daily life activities (DLAs), possibly because
of limited breathlessness. Patients often unconsciously
moderated their activities to reduce the intensity of this
distressing symptom. In general, COPD is characterised
by a gradual deterioration in lung function aggravated
by exacerbations [54]. Symptoms, functional status, and
health-related quality of life (HRQoL) may follow different
trajectories, and this discordance between functional and
health outcomes results from a complex interaction of
different variables, such as changes in health expectations,
activity levels, and physical reconditioning. In fact, adher-
ence might be more related to the patient’s beliefs about
how he is feeling than to the spirometry results. Dyspnea
and fatigue begin to have an impact on DLAs, and thus
DLAs become limited but are not eliminated. Whether a
DLA is eliminated depends on the relationship between
the need or desirability of that activity and the difficulty in
doing it because of the intensity of the associated symp-
toms. DLAs such as leisure activities are often the first
activities to be eliminated, as they generally require greater
effort and are not critical to daily life [55].
Adherent patients have better self-management, which
is related to better knowledge about their illness and
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more adherent patients had fewer exacerbations and
required fewer visits to the health centre.
Related to treatment, the prescription of Beta-2 ad-
renergic agonists and xanthine was associated with no
adherence, and having fewer devices was associated
with adherence. Thus, polypharmacy is directly related
to non-adherence [15,16,34]. Moreover, Beta-2 adrener-
gic agonists allow patients to end symptoms quickly,
causing them to intake more doses than are prescribed,
which consequently leads to non-adherent status.
Strengths and limitations
This study has several strengths. First, it is a randomised
controlled trial, regarded as the gold standard for asses-
sing the effectiveness of treatments. The random alloca-
tion of patients reduced the probability that bias would
affect the outcomes [56]. Second, we standardised the
intervention. The working plan was structured in an
exhaustive manner, and the intervention was performed
by two professionals trained in communication, know-
ledge of COPD and the inhalation techniques associated
with the different devices used by these patients. Fur-
thermore, we designed a manual for the researchers that
explained the working plan, the different parts of the
intervention, the protocol scheme outlining what to
measure each time and the details to assess each variable
included in the study. Therefore, the procedure can be
replicated elsewhere. Third, although the measure of
adherence was performed using an indirect method, the
dose/pill count has been used in outpatient practices as
the reference standard to define the diagnostic validity
of self-reported methods [37,57,58]. The main disadvan-
tage of the dose/pill count is that it assumes that every
missing dose/pill from the package has been taken by
the patient; thus, it could overestimate the prevalence of
treatment adherence. However, this method is simple,
readily available and less expensive than other methods.
No perfect gold standard exists owing to the nature of
the process that we are studying, and thus, we assume
the imperfect gold standard bias is present in our study
[59]. Fourth, patient beliefs, experiences, and behaviours
with regard to both the disease and the treatment were
found to be more powerful predictors of medication
adherence than sociodemographic and clinical factors in
patients with COPD [15,22,35]. We therefore explored
why the recommended therapeutic regimen was not
completed in the first part of the intervention (group
session) and in the individual visits. In the group session,
qualitative methods such as the focus group technique
were used to explore the beliefs and attitudes of the
patients, while in the individual visits, this information
was used to design individual interviews to focus on
motivational aspects to improve treatment adherence,using techniques from the motivational interview. Thus,
the behavioural changes would be more permanent.
This study also has several limitations. The first limita-
tion is the selection bias resulting from the missing data.
To diminish this bias, we applied several strategies: an
increase of 20% in the sample size (expected losses),
three phone calls on different days and at different times
for unreachable patients and additional appointments
for the patients who did not attend the clinic visits
(three different appointments). Despite this, we had a
dropout percentage that was higher than expected. We
analysed the similarities between the initial sample and
the final sample, and several differences were found
(spirometric pattern and the percentage of FEV1 and
FVC). However, these differences were related to illness
progression rather than to adherence. The loss of lung
function appears to be accelerated and therefore more
relevant in the early stages of COPD [60,61]. To confirm
this assumption, we analysed the patients who attended
the last visit and found a change in the spirometric pattern
from an obstructive to a mixed pattern, an increase in the
severity and a decline in FEV1 and FVC scores between
the first and last visits. This progression to a more severe
stage of the disease could explain the higher prescription
level of oral corticosteroids in the final sample. The differ-
ences found in the number of exacerbations, the number
of visits to a primary care centre and the number of visits
because of COPD were statistically significant in the inter-
vention group (the number is lower at the end of study).
This finding could be explained by the intervention
design, which may have contributed to an improvement
in the self-management of COPD in these patients as a
result of better knowledge about their illness and inhal-
ation techniques. The nature of the applied intervention
requires that patients determine their own lack of
knowledge through the motivational interview. In the
control group, only the number of visits to a primary
care centre was different between baseline and the final
visit (lower at the end of study), possibly because of the
therapeutic effect (Hawthorne effect) of the follow-up
visits. Another possible bias is the restrictive criteria
that were used for patient selection. Patients included
in the study had to have prescriptions for drugs whose
doses could be counted, thus affecting the ability to
generalise the results. However, in previous studies [38],
our group has established a strategy based on the use of
indirect methods to measure adherence in patients with
devices that cannot be counted.
Conclusion
Non-adherence is a significant health problem around
the world because it contributes to adverse health out-
comes, reduced quality of life and increased healthcare
expenditures. However, this is an aspect of therapy that
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step to adequate treatment. Our data show that the use
of educational intervention can contribute to adherence
in COPD patients and can allow us to better understand
the complex concept of adherence. We must, however,
take into account that adherence requires a behavioural
change and that this aspect is related to individual inter-
ests and expectations, meaning that patients must be
managed individually.
The findings of this randomised controlled trial show
that a multifactorial intervention (COPD information, dose
reminders, audio-visual material, motivational aspects and
training in inhalation techniques) in COPD patients is as-
sociated with an increased benefit of 48% in the adherence
to prescribed treatment. The intervention improved in a
14.8% the percentage of adherent patients comparing with
no intervention, but we have to consider the intervention
is complex and time-consuming. From the point of view
of clinical significance it could be necessary to conduct a
cost-effectiveness analysis of these results. Nevertheless,
the results remained robust after controlling for potential
confounder factors and losses and there are promising
results in relation to inhalation techniques that should
be consider for future research. Considering the magni-
tude of this health problem, physicians and nurses
should consider the opportunity to intervene with these
patients to ensure better health outcomes.
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